%PDF-1.4
%
69 0 obj
<>
endobj
66 0 obj
<>
endobj
450 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T14:10:25Z
2024-03-28T13:38:05-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:38:05-07:00
application/pdf
Heather
2003-976.oct
uuid:b9e979ec-1dd1-11b2-0a00-0e0a277d8900
uuid:b9e979ee-1dd1-11b2-0a00-d30000000000
endstream
endobj
55 0 obj
<>
endobj
56 0 obj
<>
endobj
70 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
477 0 obj
[482 0 R]
endobj
478 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6234 0.7818 -0.7818 0.6234 10.4844 52.3976 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 587 -785 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
39.97 81 m
544.97 81 l
S
0 0 0 0 k
480.79 73.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 527.968 60.9344 Tm
(1917)Tj
ET
0 0 0 0 k
40.03 75 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 41.032 62.0695 Tm
[(W)92 (asserman, et al: Reactions to infliximab)]TJ
/T1_2 1 Tf
0.0755 Tw 10 0 0 10 41.5 738.3264 Tm
(pruritis, headache, etc.\), and only 2.7% of patients discon-)Tj
0.0182 Tw 0 -1.2 TD
[(tinued therapy due to infusion-related reactions. )18 (W)80 (e did not)]TJ
0.14999 Tw T*
(assess any potential correlation between the frequency of)Tj
0.02499 Tw T*
(infusion reactions and clinical response.)Tj
0.1924 Tw 1.2 -1.2 Td
(The incidence of infusion reactions to infliximab was)Tj
-0.007 Tw -1.2 -1.2 Td
[(similar at the 3 mg/kg dose compared to 5 mg/kg dose. )18 (This)]TJ
-0.032 Tw T*
(suggests that escalating the dose of infliximab from 3 mg/kg)Tj
-0.0145 Tw T*
(to 5 mg/kg does not increase the frequency of infusion reac-)Tj
0.2486 Tw T*
[(tions. )18 (This is noteworthy)65 (, as a significant proportion of)]TJ
0.2025 Tw T*
[(patients with severe RA)-398 (do not respond adequately to 3)]TJ
0.02499 Tw T*
(mg/kg infliximab and require dose escalation.)Tj
0.125 Tw 1.2 -1.2 Td
(Previous data \(Centocor Inc., personal communication;)Tj
0.09261 Tw -1.2 -1.2 Td
(2002\) as well as our own preliminary findings established)Tj
-0.0071 Tw T*
(that infusion reactions to infliximab appear to be most com-)Tj
-0.0076 Tw T*
(mon at weeks 6 \(infusion 3\) and 14 \(infusion 4\) of the treat-)Tj
0.35181 Tw T*
(ment regimen. Our study confirmed these findings by)Tj
0.1416 Tw T*
(demonstrating that 43% of all reactions occurred at these)Tj
-0.02541 Tw T*
(infusions. On this account, we attempted to reduce infusion-)Tj
0.0007 Tw T*
[(related reactions at these 2 timepoints. However)40 (, our results)]TJ
0.05901 Tw T*
(indicated that pretreatment with diphenhydramine failed to)Tj
0.03751 Tw T*
(reduce the frequency of infusion reactions in patients with-)Tj
-0.0081 Tw T*
[(out prior reactions at infusions 3 and 4. )18 (Whether prophylax-)]TJ
0.0611 Tw T*
(is in patients with prior reactions reduced the frequency of)Tj
-0.0208 Tw T*
[(subsequent infusion-related reactions remains unclear)40 (, since)]TJ
0.04089 Tw T*
(all patients were given prophylaxis after an initial reaction.)Tj
0.2422 Tw T*
(Of importance, a significant number of the reactions in)Tj
0.2428 Tw T*
(those patients pretreated with diphenhydramine included)Tj
-0.0251 Tw T*
(pruritis, flushing, hypotension, and headache, which may be)Tj
0.14011 Tw T*
[(explained by the known side ef)18 (fects of the antihistamine.)]TJ
0.0269 Tw T*
(These data suggest that other forms of prophylaxis, such as)Tj
0.0108 Tw T*
(steroids or long-acting antihistamines, may be more benefi-)Tj
-0.0164 Tw T*
(cial than diphenhydramine. Our data do not support the pro-)Tj
0.28 Tw T*
(phylactic use of diphenhydramine at infusions 3 and 4)Tj
0.02499 Tw T*
(unless a prior reaction has occurred.)Tj
0.0323 Tw 1.2 -1.2 Td
(In contrast to data reported by Maini, )Tj
/T1_1 1 Tf
15.3867 0 Td
(et al)Tj
/T1_2 1 Tf
-0.0491 Tc 0 Tw 7.5 0 0 7.5 225.1855 333.6265 Tm
(11)Tj
0 Tc 0.0322 Tw 10 0 0 10 232.3169 330.3264 Tm
(, we did not)Tj
-0.00011 Tc 0.0486 Tw -19.0817 -1.2 Td
(find that the frequency of infusion reactions was highest at)Tj
0.14751 Tw T*
[(the initial infusion. )18 (W)80 (e did note that the type of infusion)]TJ
0.1266 Tw T*
[(reaction was related to the treatment course, with aller)18 (gic)]TJ
0.0787 Tw T*
(and cardiopulmonary reactions occurring later in the treat-)Tj
0.02499 Tw T*
(ment regimen than miscellaneous reactions.)Tj
0.36571 Tw 1.2 -1.2 Td
[(In summary)65 (, infusion-related reactions to infliximab)]TJ
0.06509 Tw -1.2 -1.2 Td
(treatment were frequent, but almost always mild, with few)Tj
0.1622 Tw 26.3 49.2 Td
(patients discontinuing treatment on the basis of the reac-)Tj
0.0685 Tw T*
(tions. Escalated infliximab dosing did not increase the fre-)Tj
0.1282 Tw T*
(quency of infusion reactions, while antihistamine prophy-)Tj
0.1102 Tw T*
(laxis with diphenhydramine failed to reduce the increased)Tj
0.04539 Tw T*
(frequency of infusion reactions at the 3rd and 4th infusion.)Tj
0.0116 Tw T*
(Indeed, prophylactic treatment appeared to increase the fre-)Tj
0.0778 Tw T*
[(quency of adverse events. )18 (These data suggest that prophy-)]TJ
0.0217 Tw T*
(lactic therapy with the antihistamine diphenhydramine may)Tj
0.0096 Tw T*
(be indicated only for patients experiencing a prior infusion-)Tj
0.0341 Tw T*
(related reaction, while other modes of pretreatment such as)Tj
0.0072 Tc 0.36771 Tw T*
[(long-acting antihistamines should be evaluated. )18 (T)70 (aken)]TJ
-0.00011 Tc -0.0181 Tw T*
[(together)40 (, our data suggest that infliximab is well tolerated in)]TJ
0.02499 Tw T*
(patients with severe, long-standing, DMARD-resistant RA.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 311.5 560.3264 Tm
[(1.)-875 (Feldmann M, Maini RN. )55 (Anti )18 (TNF-a therapy of rheumatoid )]TJ
0 Tc 1.675 -1.25 Td
[(arthritis. )55 (Annu Rev Immunol 2000;19:163-96.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875 (Keystone EC. )18 (T)35 (umor necrosis factor)20 (-alpha blockade in the )]TJ
1.675 -1.25 Td
[(treatment of rheumatoid arthritis. Rheum Dis Clin North )55 (Am)]TJ
0 Tc 0 Tw 0 -1.25 TD
(2001;27:427-43.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875 (V)60 (ilcek J. )18 (The cytokines: an overview)65 (. In: )18 (Thomson )55 (A)80 (W)92 (, editor)55 (. )18 (The)]TJ
1.675 -1.25 Td
[(cytokine handbook. New )37 (Y)100 (ork: )55 (Academic Press; 1998:1-20.)]TJ
-1.675 -1.25 Td
[(4.)-875 (Feldmann M, Dower S, Brennan FM. )18 (The role of cytokines in )]TJ
1.675 -1.25 Td
(normal and pathological situations. In: Brennan FM, Feldmann M,)Tj
T*
[(editors. Role of cytokines in autoimmunity)65 (. )55 (Austin: RG Landes)]TJ
T*
(Co., Medical Intelligence Unit; 1996:1-23.)Tj
-1.675 -1.25 Td
[(5.)-875 (Aggarwal BB, Samanta )55 (A, Feldmann M. )18 (TNF-a. In: Feldmann M,)]TJ
1.675 -1.25 Td
[(editor)55 (. )18 (The cytokine reference. New )37 (Y)100 (ork: )55 (Academic Press; 2000.)]TJ
-1.675 -1.25 Td
[(6.)-875 (V)111 (assalli P)111 (. )18 (The pathophysiology of tumor necrosis factors. )55 (Annu)]TJ
1.675 -1.25 Td
[(Rev Immunol 1992;10:41)37 (1.)]TJ
-1.675 -1.25 Td
[(7.)-875 (Y)100 (okota S, Geppert )18 (T)74 (, Lipsky P)111 (. Enhancement of antigen- and )]TJ
1.675 -1.25 Td
[(mitogen-induced human )18 (T)-257 (lymphocyte proliferation by tumor)]TJ
T*
[(necrosis factor)20 (-a. J Immunol 1988;140:531-6.)]TJ
-1.675 -1.25 Td
[(8.)-875 (Gordon C, )18 (W)80 (ofsy D. Ef)18 (fects of recombinant murine tumor necrosis)]TJ
1.675 -1.25 Td
[(factor)20 (-a on immune function. J Immunol 1990;144:1753-8.)]TJ
-1.675 -1.25 Td
[(9.)-875 (Knight DM, )18 (T)35 (rinh H, Le J, et al. Construction and initial )]TJ
1.675 -1.25 Td
[(characterization of a mouse-human chimeric anti-TNF antibody)65 (.)]TJ
T*
(Mol Immunol 1993;30:1443-53.)Tj
-2.175 -1.25 Td
[(10.)-875 (V)60 (ictor FC, Gottlieb )55 (AB. )18 (TNF-alpha and apoptosis: implications for)]TJ
2.175 -1.25 Td
(the pathogenesis and treatment of psoriasis. J Drugs Dermatol)Tj
0 Tc 0 Tw T*
(2002;1:264-75.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (Maini R, St. Clair EW)92 (, Breedveld F)80 (, et al. Infliximab \(chimeric)]TJ
2.1381 -1.25 Td
(anti-tumour necrosis factor alpha monoclonal antibody\) versus)Tj
T*
(placebo in rheumatoid arthritis patients receiving concomitant)Tj
T*
(methotrexate: a randomised phase III trial. Lancet )Tj
0 Tc 0 Tw T*
(1999;354:1932-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875 (Centocor Inc. Personal communication to Dr)55 (. E.C. Keystone; 2002.)]TJ
ET
0 0 0 0 k
/GS0 gs
95.75 86.08 396.48 -10.83 re
f*
0.5 w
95.75 86.08 396.48 -10.83 re
S
Q
Q
q
1 0 0 1 0 8 cm
0 0 612 792 re
W n
1 0 0 1 0 -8 cm
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_4 8 Tf
110.368 77 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
49 0 obj
<>stream
8;Z\7!HJ8c#k\-=j?%5IAC2NWS0jG[gM&]l&9h2T6?M^8OFD1t'Td;EYb?(pK/e#u
f4p:'/^ZaL+=-]kfi\T[=FW9k/,+L&4sT=>dE\@t21\
<>eT$f0JEDKXY]\ASY"G?6>=aKO:K=(TC3%s#23d/Z!6:q`ch'=&-:cLDh+`DdJjd
*M8BHl%JN^7m8Pucd\h:V)$&qjsZL2Y"W9,!>Al@XUs`pGtfjSdRa/p-EBuVIZ[/E
).3".H1=(m/FEVYm[5!\Q:FgjVJh".qa)'b5BZnh4b)Qu5!cGX-Pa6A(IkGTC)Rj@
"?u^Uj>_4s[WmecA/LREiFhjj9bPGls%'_+2@2<;6f='XjJn5Fpreo=9'&[!
b`MQ6++CEb1nDnO;(?q(J?[\7)sWfEWas1NVn;C6mT&8gq4*@a+m(QfNHUQ`#LpHr
Hu;M?^DphR7J:NXYTC3pO"I6?EiC1]?B-BRJD7]El]DG+[OUIW"3Xo!hCa-$%LrsY
%_`n\Vq-DF.9j_M(VW^>WJYq?E%m3B!
endstream
endobj
53 0 obj
[/Indexed/DeviceRGB 255 52 0 R]
endobj
52 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
126 0 obj
<>
endobj
77 0 obj
<>
endobj
82 0 obj
<>
endobj
36 0 obj
<>
endobj
113 0 obj
<>
endobj
456 0 obj
<>
endobj
37 0 obj
<>
endobj
38 0 obj
<>stream
HLPw9v_lEY=I1WCiB$QS%p~aAqww`P "FaAFEL:N4IZkHgfgwyg>wI": I2nuVVVE,6+1a-UOS$=!#QfGK9x?y⎐i5:#(9(?dqRR*ZYV?_/IOK~AkZӓRVUa\{Cp:ct1gY|\&J9}x#_!KM6P;|vxE[{ʭ.K(XL.=a x hHK5,eDD4#1L%DuSB4PTwLA2OKu9Gm
?bBdЖYk)5W-"6?`[[䠒n)roUy3t߂QZϰ<